The pharmaceutical firm Novo Nordisk is pursuing a multi-pronged strategy to regain market share that it has lost to Eli Lilly in the lucrative obesity drug market.

Novo Nordisk is racing to capture more patients now that many compounding pharmacies are restricted from making Wegovy copycats, with rare exceptions.

Novo Nordisk A/S said it would sell its popular weight-loss drug Wegovy for a steeply reduced price on several telehealth platforms. The strategy comes as rival Eli Lilly & Co. is working with telehealth firms to distribute lower-cost vials of its own obesity medication,